Immunome Inc. 4

Immunome Inc. Chief Scientific Officer Jack Higgins received 38,250 RSUs and 76,500 stock options on Immunome common stock as equity awards.

On July 23, 2026, Immunome Inc. Chief Scientific Officer Jack Higgins received an equity compensation package consisting of 38,250 restricted stock units (each convertible into one share of common stock) and a stock option grant for 76,500 shares at an exercise price of $22.01 per share, both reported as awards rather than open-market purchases. The RSUs will vest annually over four years in 25% tranches, while the options vest 25% on July 23, 2027, with the remaining shares vesting monthly over the following three years, all contingent on continued service. Following these grants, Higgins reported direct beneficial ownership of 60,250 common shares and an additional 76,500 option shares underlying the new award, and also disclosed three 1,000-share custodial accounts held as custodian for his children, for which he disclaims beneficial ownership.

Filing Facts

CIK

1472012

Ticker

IMNM

Form

4

Source Type

fda

Accession

0001993684-26-000006

Alert Tier

5